<DOC>
	<DOCNO>NCT01349010</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety import Probucol hyperlipidemia patient .</brief_summary>
	<brief_title>Efficacy Safety Imported Probucol Treat Hyperlipidemia</brief_title>
	<detailed_description>This randomize , double blind , placebo control , multi-centre clinical study hyperlipidemia patient . Enrolled subject randomize treatment group control group , receive Probucol placebo continuously 8 week ; Treatment group : Imported Probucol 250 mg ( 1 tablet ) bid . p.o Control group : Placebo 1 tablet bid . p.o</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>1 . Signing Informed Content Form ; 2 . Age &gt; = 20 ( age time sign ICF ; gender ) ; 3. hyperlipidemia patient meet follow criterion : 4.14 mmol/L ( 160mg/dL ) = &lt; LDLC ( Serum low density lipoproteincholesterol ) &lt; 6 mmol/L ( 232mg/dL ) TG ( Serum triglyceride ) &lt; 4.5 mmol/L ( 398mg/dL ) ; 4 . Framingham : Coronary Heart Disease 2year risk probability &lt; 10 % . 1 . Subjects receive antilipemic agent within 1 month prior prescreening period ; 2 . Subjects receive Probucol within 6 month prior prescreening period ; 3 . Coronary Heart Disease subject ; 4 . Subjects treat cyclosporine ; 5 . Subjects history hypersensitivity Probucol ; 6 . QTc interval &gt; 450ms ( male ) ; QTc interval &gt; 470ms ( female ) ; 7 . Subjects impaired hepatic renal function , meet follow abnormal value : AST &gt; = 100IU/L ALT &gt; = 100IU/L Serum creatinine &gt; = 1.5mg/dL 8 . Female subject pregnant , lactate , plan conceive ; 9 . Subjects consider investigator inappropriate participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hyperlipidemia</keyword>
</DOC>